Systemic therapies for squamous cell carcinoma of the head and neck.
OBJECTIVE
To discuss current clinical recommendations for treatment of squamous cell carcinoma of the head and neck (SCCHN), to identify common toxicities associated with combined chemoradiotherapy or chemotherapy alone, and describe strategies for management of the most common treatment-related toxicities.


METHODS
Current research, published literature, National Comprehensive Cancer Network Clinical Practice Guidelines, American Society of Clinical Oncology, and Oncology Nursing Society.


CONCLUSIONS
Advances in options for systemic therapy for SCCHN have provided hope for patients with this disease. However, effective management of these patients requires a proactive and persistent multidisciplinary treatment approach, including toxicity management.


CONCLUSIONS
Careful evaluation of each patient before initiating treatment with the goals of therapy reviewed by the multidisciplinary team, the patient, and the caregivers, will allow selection of the most appropriate treatment plan. The goals of therapy should provide guidance in balancing tumor response, toxicity (both acute and late effects), survival, and quality of life.
Kurtin
Sandra E
SE
Arizona Cancer Center, 3838 N.Campbell Ave, Tucson, AZ 85719, USA. skurtin@umcaz.edu
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000451:nursing / Q000532:radiotherapy; D003131:Combined Modality Therapy; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000451:nursing / Q000532:radiotherapy; D006801:Humans; D009362:Neoplasm Metastasis; D011878:Radiotherapy / Q000009:adverse effects; D012008:Recurrence
D000970:Antineoplastic Agents